NFE2L2 and chronic myelogenous leukemia, BCR-ABL1 positive: Also, It has been shown that the combination of TPL with DOX and imatinib could reduce HIF-1α, Nrf2 expression, and drug resistance in HL60/A (AML) and K562/G (CML) cell lines.